ReviewInfection2009
Reducing the burden of influenza-associated complications with antiviral therapy.
Review in Infection, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Pooled it
- Article
- Article
- Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: A structural equation modelling approach.Influenza and other respiratory viruses · 2017Article
- Incidence and Risk Factors of Pneumonia in Hospitalized Patients with Seasonal Influenza A or B.Tuberculosis and respiratory diseases · 2017Article
- Pneumonia and influenza, and respiratory and circulatory hospital admissions in Belgium: a retrospective database study.Archives of public health = Archives belges de sante publique · 2014Article
- Body mass index and the incidence of influenza-associated pneumonia in a UK primary care cohort.Influenza and other respiratory viruses · 2012Article
- Delay in diagnosis of influenza virus in an elderly hospitalized patient: a fatal outcome.Clinical medicine insights. Case reports · 2012Article
- Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.Advances in therapy · 2011Review
- Parasite-mediated upregulation of NK cell-derived gamma interferon protects against severe highly pathogenic H5N1 influenza virus infection.Journal of virology · 2011Article
- [Influenza : clinical symptoms, diagnostics and therapy].Der Internist · 2011Article
- Platelet-activating factor receptor plays a role in lung injury and death caused by Influenza A in mice.PLoS pathogens · 2010Article
- Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.Clinical pharmacokinetics · 2010Review
- Review
- A cross-sectional survey to evaluate knowledge, attitudes and practices (KAP) regarding seasonal influenza vaccination among European travellers to resource-limited destinations.BMC public health · 2010Article
- Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.The Journal of antimicrobial chemotherapy · 2010Review
- Lymphocyte to monocyte ratio as a screening tool for influenza.PLoS currents · 2010Article
- Bench-to-bedside review: bacterial pneumonia with influenza - pathogenesis and clinical implications.Critical care (London, England) · 2010Review
- The novel influenza A (H1N1) virus pandemic: An update.Annals of thoracic medicine · 2009Article
- Influenza moves to the front of public health concerns.Infection · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInfluenza imposes an annual burden on individuals, society, and healthcare systems. This burden is increased by the development of complications that are often more severe than the primary infection. Here, we examine the main complications associated with influenza and review the effectiveness of antiviral therapy in reducing the incidence of such events. MATERIAL AND
methodsThe content of this review is taken from the study of the authors' extensive collection of reference materials, examination of the bibliographical content of relevant papers, and the results of Medline searches.
resultsThe most commonly encountered complications in adults are sinusitis, pharyngitis, bronchitis, and, particularly in the elderly, bacterial pneumonia. Such complications may exacerbate pulmonary complaints. Children are particularly prone to post-influenza croup and otitis media. Complications involving the central nervous system, heart, or skeletal muscle also occur in influenza patients. Influenza-associated complications impose sizeable healthcare costs in terms of outpatient contacts, hospitalizations, and antibiotic use. Vaccination is the primary prevention strategy for influenza and its complications, but has limitations. Neuraminidase inhibitors have demonstrated efficacy in reducing the incidence of influenza-associated complications in populations with different ages and risks.
conclusionsInfluenza complications place a large burden on healthcare providers and society. Neuraminidase inhibitors can reduce the incidence of such complications, particularly in high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.